Andrey Nikolaevych Belousov, MD, PhD
Head Laboratory of Applied Nanotechnologies
Education and Academic Degrees:
-
MD, Kharkiv Medical Institute, Ukraine (1988)
-
Doctor of Medicine (Anesthesiology and Intensive Care), Kharkiv National Medical University (2004)
Dissertation:
"Extracorporeal hemocorrection using magnet-controlled sorbent in intensive therapy of intoxication syndromes in patients with hepatopancreatoduodenal diseases", (2004)
Research Contributions:
Professor Belousov is the developer of the world’s first clinically approved and officially registered nanotechnology-based drugs (1995), implemented in medical practice. His pioneering work established a new field in applied nanomedicine.
Innovations in Nanotechnology-Based Medicine:
-
Micromage-B — oral preparation based on magnetite nanoparticles (Fe₃O₄, 6–12 nm); officially registered in Ukraine as a biologically active additive.
-
MCS-B — magnet-controlled sorbent for extracorporeal detoxification of biological fluids; officially registered and approved for medical practice in Ukraine.
-
ICNB (NanoBiocorrector) — an intravenous intracorporal nanosorbent for systemic detoxification and blood rheology correction.
Scientific Achievements:
-
Author of a novel method of extracorporeal hemocorrection using magnet-controlled sorbents (MCS-B).
-
Recipient of the European Medical Diploma “An Honorary Scholar of Europe” and the Robert Koch Medal (2008) for contributions to medical nanotechnology and innovative therapeutic methods.
Research Interests:
Nanomedicine, detoxification technologies, extracorporeal therapies, critical care pharmacology, and rheological correction of blood.
Current Position:
Head of the Laboratory of Applied Nanotechnologies, leading multidisciplinary research on the clinical application of nanostructured materials in medicine with a focus on personalized and non-invasive therapies.
Collaboration and Partnerships:
Professor Belousov and his research group are actively seeking collaborations with pharmaceutical companies, biotechnology enterprises, and academic institutions interested in developing next-generation nanomedicine platforms. Opportunities include:
-
Licensing and co-development of patented nanotechnology-based drugs (Micromage-B, MCS-B, ICNB).
-
Joint clinical trials and translational research in nanomedicine and detoxification technologies.
-
Strategic partnerships for scaling production, regulatory approval, and global market expansion.
-
Participation in international research consortia, innovation programs, and competitive grants.
The Laboratory of Applied Nanotechnologies welcomes partnerships to accelerate the translation of nanotechnology breakthroughs into clinically relevant, safe, and effective therapies worldwide.
SOME RESULTS OF RESEARCH:
